James Provenzale, MD
Department of Radiology
Division of Neuroradiology
Duke University Medical Center
Neil Rofsky, MD
Professor and Chairman
Effie and Wofford Cain Distinguished Chair in Diagnostic Imaging
Department of Radiology
UT Southwestern Medical Center
Mark Beautz, RT (R) (MR)
Chief Technologist / Magnetic Resonance Imaging Center
Duke University Medical Center
Estimated amount of time to complete: 30 minutes
Since the introduction of gadolinium-based contrast agents (GBCAs) into magnetic resonance imaging (MRI) in the 1980s, multiple contrast agents have been introduced and used extensively in a wide range of indications, particularly central nervous system (CNS) examinations, evaluation of neurodegenerative disease, and assessment of tumors. Contrast enhancement provides improved tissue contrast and characterization of lesions and more sensitive detection of smaller lesions.
GBCAs differ in physicochemical characteristics and function, and their stability, concentration, and relaxivity can have a significant impact on their efficacy and safety in clinical applications. GBCA stability relates to safety, while relaxivity and concentration contribute to the level of image enhancement that can be achieved when performing contrast MRI. These characteristics must be taken into consideration to provide the most efficacious and safe procedures for patients needing MRI for disease diagnosis and assessment of therapy response.
Radiologists and other health care professionals interested or involved in diagnostic imaging and its role in patient diagnosis and management.
Attention radiologic technologists: This activity is approved by ASRT for 0.5 Category A+ continuing education credit. To access this version of the activity, please click here. Learning Objectives
Upon completion of this educational activity, the participant should be able to:
Differentiate contrast choices and dosing options available for MR imaging of the central nervous system.
Identify the potential role of new and emerging contrast agents and imaging techniques for MRI in patients with CNS disorders.
Explore how advances in contrast development and imaging protocols may impact future treatment decisions for patients with CNS disorders.
It is the policy of the Temple University School of Medicine, The Albert J. Finestone, M.D., Office for Continuing Medical Education that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Temple University School of Medicine, Office for Continuing Medical Education has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosures are provided below.
Planning committee members have no financial relationships to disclose.
The information presented in this CME program represents the views and opinions of the individual contributors, and does not constitute the opinion or endorsement of, or promotion by, Temple University School of Medicine, Temple University Health System or its affiliates. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each activity participant must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
Dr. Provenzale discloses that he receives grant/research support from GE Medical Healthcare and Bayer HealthCare Pharmaceuticals. He also serves as a consultant for Millennium and Theradex and is a stockholder in Amirsys, Inc.
Dr. Rofsky has no relevant financial relationships with any commercial interests to disclose.
Mr. Beautz has no relevant financial relationships with any commercial interests to disclose.
Accreditation Statement: Temple University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor Continuing Medical Education for physicians.
Certification Statement: Temple University School of Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
There is no fee to participate and receive credit.
Attention radiologic technologists: This activity is approved by ASRT for 0.5 Category A+ continuing education credit. To access this version of the activity, please click here.
Credit Provider Contact Information
School of Medicine
The Albert J. Finestone, MD Office for CME
3500 North Broad Street Philadelphia, PA 19140
Commercial Support Statements
This educational activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals.
Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers
The next screen will permit you to check for or download the Flash player required to run this program and to begin the program presentation. The activity will take approximately 30 minutes to complete.
After the activity has finished, click on the "Post-test" button.
Instructions for completing and submitting the post-test and evaluation are provided on the post-test screen.
Please turn off all pop-up blockers to assure access to the educational activity.
Click on the "Start program" icon at the bottom of this page. If you are not already registered as a user of this website, this will bring you to the login/registration page where you will be able to register as a new CMEcorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
Copyright © 2012. Temple University School of Medicine. All rights reserved.
Presented by Temple University School of Medicine and Medical Communications Media, Inc.
The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Temple University School of Medicine, or Bayer HealthCare Pharmaceuticals. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.
To view our privacy policies, please visit: http://www.cmecorner.com/privacy.asp